Mesoblast Limited (MESO) News

Mesoblast Limited (MESO)

Today's Latest Price: $15.28 USD

1.46 (-8.72%)

Updated Nov 25 4:00pm

Add MESO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter MESO News Items

MESO News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest MESO News From Around the Web

Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Mesoblast plunges on FDA recommendation of additional study for remestemcel-L in SR-aGVHD

The FDA has issued a Complete Response Letter to Mesoblast's (MESO) Biologics License Application ((BLA)) for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).While the Oncologic Drugs Advisory Committee of the FDA voted 9:1 that the available data support the efficacy of remestemcel-L in pediatric...

Seeking Alpha | October 2, 2020

The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates

Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. ...

Benzinga | September 26, 2020

Mesoblast (ASX:MSB) wins Biotech award for Remestemcel-L

15 Sep 2020 - Mesoblast (ASX:MSB), today announced that its lead product candidate remestemcel-L has been selected as the winner of the Fierce Innovation Awards - Life Sciences Edition 2020 for Biotech Innovation.

Finance News Network | September 14, 2020

Late-stage study of Mesoblast cell therapy in COVID-19 to continue as is

The independent Data Safety Monitoring Board has completed its first interim analysis of data from a Phase 3 clinical trial evaluating Mesoblast Limited's ([[MESO]] -0.3%) remestemcel-L, an allogeneic mesenchymal stem cell product derived from bone marrow, in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome ((ARDS)).Based on preliminary results from...

Seeking Alpha | September 4, 2020

Mesoblast's (ASX:MSB) good COVID-19 news | Rask Media

Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.

Rask Media | September 4, 2020

Buy, hold, sell: Telstra, CSL, Mesoblast, Dacian Gold, EML Payments

These stocks are the most searched-for on Livewire Markets – but are they a buy?

The Australian Financial Review | September 3, 2020

Mesoblast nabs ethics approval to treat COVID-19 patients in Australia

Mesoblast (MESO) has received approval from the Human Research Ethics Committee of Monash Health to include Australian hospitals in the Phase 3 trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome ((ARDS)). Up to 300 patients are expected to be enrolled in this late-stage study.The clinical protocol...

Seeking Alpha | September 2, 2020

The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics...

Benzinga | September 2, 2020

Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients

02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).

Finance News Network | September 1, 2020

Mesoblast Before The PDUFA

Mesoblast's (MESO) stock has grown over 300% since we last made out an investment case in March 2019, and an IOM runthrough six months prior, based on phase 2 trial data in acute graft versus host disease (aGVHD). Presently, the United States Food and Drug Administration ((FDA)) has accepted the...

Avisol Capital Partners on Seeking Alpha | August 31, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.646 seconds.